For research use only. Not for therapeutic Use.
Ulipristal acetate (Cat.No:I001073) is a synthetic selective progesterone receptor modulator (SPRM) used as an emergency contraceptive pill and for the treatment of uterine fibroids. It works by inhibiting ovulation and altering the endometrial lining, preventing implantation. Ulipristal acetate provides an effective and safe option for contraception and managing certain gynecological conditions.
| Catalog Number | I001073 |
| CAS Number | 126784-99-4 |
| Synonyms | [(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate |
| Molecular Formula | C30H37NO4 |
| Purity | ≥95% |
| Target | Estrogen/progestogen Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20℃ |
| IUPAC Name | [(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate |
| InChI | InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1 |
| InChIKey | OOLLAFOLCSJHRE-ZHAKMVSLSA-N |
| SMILES | CC([C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(N(C)C)C=C5)C[C@]12C)=O)=O |
| Reference | </br>1:An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome. Chen BF, Powell MC, O/’Beirne C.J Obstet Gynaecol. 2017 May 12:1-4. doi: 10.1080/01443615.2017.1287687. [Epub ahead of print] PMID: 28498002 </br>2:Endometrial changes during ulipristal acetate use: A systematic review. De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK.Eur J Obstet Gynecol Reprod Biol. 2017 Apr 28;214:56-64. doi: 10.1016/j.ejogrb.2017.04.042. [Epub ahead of print] Review. PMID: 28482329 </br>3:Ulipristal acetate: An update for Australian GPs. Mazza D.Aust Fam Physician. 2017;46(5):301-304. PMID: 28472576 Free Article</br>4:Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment? Pourcelot AG, Capmas P, Fernandez H.J Gynecol Obstet Hum Reprod. 2017 Mar;46(3):249-254. doi: 10.1016/j.jogoh.2017.02.001. Epub 2017 Feb 3. PMID: 28403922 </br>5:Pregnancy Outcomes Following Ulipristal Acetate Emergency Contraception Failure: A Report of Five Cases. Ozturk Z, Akgul E.Fetal Pediatr Pathol. 2017 Apr 3:1-7. doi: 10.1080/15513815.2017.1303010. [Epub ahead of print] PMID: 28368774 </br>6:Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy? Luketic L, Shirreff L, Kives S, Liu G, El Sugy R, Leyland N, Solnik MJ, Murji A.J Minim Invasive Gynecol. 2017 Mar 25. pii: S1553-4650(17)30227-3. doi: 10.1016/j.jmig.2017.02.025. [Epub ahead of print] PMID: 28351762 </br>7:Safety after extended repeated use of ulipristal acetate for uterine fibroids. Fauser BC, Donnez J, Bouchard P, Barlow DH, Vázquez F, Arriagada P, Skouby SO, Palacios S, Tomaszewski J, Lemieszczuk B, William AR.PLoS One. 2017 Mar 7;12(3):e0173523. doi: 10.1371/journal.pone.0173523. eCollection 2017. PMID: 28267814 Free PMC Article</br>8:Ulipristal acetate before high complexity endoscopic (hysteroscopic, laparoscopic) myomectomy – a mini-review. Baranowski W.Prz Menopauzalny. 2016 Dec;15(4):202-204. doi: 10.5114/pm.2016.65664. Epub 2017 Feb 8. Review. PMID: 28250723 Free PMC Article</br>9:Study of the effect of ulipristal acetate on human sperm ability to interact with tubal tissue and cumulus-oocyte-complexes. Zumoffen C, Gómez-Elías MD, Caille AM, Bahamondes L, Cuasnicú PS, Cohen DJ, Munuce MJ.Contraception. 2017 Feb 24. pii: S0010-7824(17)30059-8. doi: 10.1016/j.contraception.2017.02.019. [Epub ahead of print] PMID: 28238840 </br>10:Ulipristal acetate administration at mid-cycle changes gene expression profiling of endometrial biopsies taken during the receptive period of the human menstrual cycle. Lira-Albarrán S, Durand M, Larrea-Schiavon MF, González L, Barrera D, Vega C, Gamboa-Domínguez A, Rangel C, Larrea F.Mol Cell Endocrinol. 2017 May 15;447:1-11. doi: 10.1016/j.mce.2017.02.024. Epub 2017 Feb 20. PMID: 28219738 |
